Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2019

View Archived Issues

Meta-analysis reveals universally altered genes in early AD

New cholesterol target works independently of LDL receptor

Celyad opens enrollment in phase I trial of CYAD-1 for relapsed/refractory AML or MDS

Akari announces trial design for pivotal phase III study of nomacopan in pediatric HSCT-TMA

BiomX completes enrollment in cosmetic clinical study of BX-001 in acne-prone skin

Funding supports LUNAC-led project to develop next-generation anticoagulant

Neurocrine Biosciences and Xenon collaborate to develop first-in-class treatments for epilepsy

Noxopharm announces promising data from DARRT-1 study of Veyonda in prostate cancer

Seattle Genetics, Astellas, Merck & Co. collaborate to study enfortumab + Keytruda in bladder cancer

Phase IIa study of masupirdine in moderate Alzheimer's disease misses primary endpoint

Novel acute challenge mouse model to assess malaria T-cell vaccine antigens in mice

First report of a schistosome target activated by schistosomes

Phase II results for tislelizumab plus chemotherapy in GC/GEJC and ESCC

SHR-1210 plus apatinib as promising first-line treatment for advanced lung squamous carcinoma

Gilead identifies new Mcl-1 inhibitors

New Bruton tyrosine kinase inhibitors discovered at Biogen

Novo Nordisk patents melanocortin MC4 receptor agonists

Arbutus Biopharma discloses anti-HBV/HDV compounds

Nitric oxide production enhancers identified at Gurus Biopharm

One-year data reported for clinical trial of Pfs230D1M-EPA/AS01 malaria vaccination regimen

Enterotoxigenic E. coli vaccine Etvax in children and infants from Bangladesh: phase I/II results

Darobactin, new antibiotic against Gram-negative pathogens from Photorhabdus nematode symbionts

TAF1 is crucial for AML1-ETO-driven leukemogenesis

Dosing begins in phase I study of UCART-22 in relapsed/refractory B-ALL

OSE-127 phase I data pave way for phase II studies in ulcerative colitis and Sjogren's syndrome

NantKwest reports first safety data from phase I trial of PD-L1 t-haNK in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...